Suchergebnisse - "PARP inhibitor"

PubPharm (2.849)

21

Overexpression of ABCC1 and ABCG2 confers resistance to talazoparib, a poly (ADP-Ribose) polymerase inhibitor

enthalten in: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy | 2024

von Teng, Q. | Lei, Z. | Wang, J. | +9

22

TALAPRO-3 clinical trial protocol : phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer

enthalten in: Future oncology (London, England) | 2024

von Agarwal, N. | Saad, F. | Azad, A. | +8

23

Interstitial lung disease caused by niraparib in ovarian cancer patient : a case report and literature review

enthalten in: Japanese journal of clinical oncology | 2024

von Shono, M. | Murakami, K. | Ohta, M. | +2

24

Targeted Combination of Poly(ADP-ribose) Polymerase Inhibitors and Immune Checkpoint Inhibitors Lacking Evidence of Benefit : Focus in Ovarian Cancer

enthalten in: International journal of molecular sciences | 2024

von Bailey, M. | Morand, S. | Royfman, R. | +6

25

Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer : A Quantitative Synthesis and Meta-analysis

enthalten in: European urology oncology | 2024

von Messina, C. | Giunta, E. | Signori, A. | +11

26

Aryl hydrocarbon receptor suppresses STING-mediated type I IFN expression in triple-negative breast cancer

enthalten in: Scientific reports | 2024

von Martin, J. | da Silva Fernandes, T. | Chaudhry, K. | +5

27

Olaparib Combined with Abiraterone versus Olaparib Monotherapy for Patients with Metastatic Castration-resistant Prostate Cancer Progressing after Abiraterone and Harboring DNA Damage Repair Deficiency : A Multicenter Real-world Study

enthalten in: European urology oncology | 2024

von Xie, J. | Guo, H. | Dong, B. | +12

28

A novel SIK2 inhibitor SIC-19 exhibits synthetic lethality with PARP inhibitors in ovarian cancer

enthalten in: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy | 2024

von Wang, F. | Yu, X. | Qian, J. | +9

29

The cost-effectiveness of germline BRCA testing-guided olaparib treatment in metastatic castration resistant prostate cancer

enthalten in: International journal of technology assessment in health care | 2024

von Teppala, S. | Scuffham, P. | Tuffaha, H.

30

PARP Inhibitor for Neoadjuvant Therapy in HER2-Negative Breast Cancer : A Systematic Review and Meta-Analysis of Efficacy and Safety

enthalten in: Clinical breast cancer | 2024

von Jia, X. | Wang, K. | Zhuo, Q. | +2